drugset / Trial / NCT00004893
Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
Phase 2
Completed
5 enrolled
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of interleukin-12 in treating patients who have metastatic or recurrent breast cancer.
Timeline
- Start
- 1999-12
- Primary completion
- 2002-02
- Completion
- 2002-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | — | Subcutaneous |